Shares in Chinese biotech company Ascletis Pharma Inc rose as much as 6.4 percent on debut in Hong Kong on Wednesday, the first such listing in the city under new rules designed to attract drug developers.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
